Semaglutide / B12
Semaglutide + Cyanocobalamin (Vitamin B12)
—
Liquid
Semaglutide: ~7 days; B12: weeks
Refrigerate at 2–8°C, protect from light
// PAI-2026-05
Semaglutide / B12
This combination pairs the GLP-1 receptor agonist Semaglutide with Cyanocobalamin (Vitamin B12). B12 is included to support energy metabolism, neurological function, and to help mitigate fatigue that can accompany GLP-1 therapy. This formulation is designed for comprehensive metabolic support alongside weight management.
Select Quantity
5mg/2mg · Lyophilized
$158.44
per mg
$22.63
Mechanism of Action
- Semaglutide activates GLP-1 receptors for appetite control
- B12 supports mitochondrial energy production
- B12 maintains neurological function during caloric restriction
- Combined support for metabolic health
Amino Acid Sequence
Semaglutide GLP-1 analogue + Cyanocobalamin
Solubility
Liquid formulation — ready to use
Certificate of Analysis
Batch PAI-2026-05 · Issued Jul 26, 2026
99.5%
RP-HPLC · UV 220nm
Confirmed
LC-MS/MS · ESI+
<0.1 EU/mg
LAL method
<10 CFU/g
USP <61>
HPLC Purity Profile
99.5% main peak| Test | Method | Specification | Result | Status |
|---|---|---|---|---|
| Purity (HPLC) | RP-HPLC | ≥98.0% | 99.5% | PASS |
| Identity (MS) | LC-MS/MS | Conforms | Conforms | PASS |
| Appearance | Visual | White powder | Conforms | PASS |
| Moisture | Karl Fischer | ≤8.0% | 3.3% | PASS |
| Residual Solvents | GC-HS | ICH Q3C | Conforms | PASS |
| Endotoxins | LAL | <1 EU/mg | <0.1 EU/mg | PASS |
Testing performed by independent ISO-accredited laboratory. Full chromatograms and spectra available in the downloadable COA document.
Research References
GLP-1 agonists and B12 supplementation in metabolic therapy
Diabetes Care · 2022
For research purposes only. These references are provided for informational use and do not constitute medical advice.
More in Weight Management
View all →AOD-9604
≥99.5% purity · 1815.1 Da
Modified fragment of human growth hormone studied for fat metabolism, lipolysis stimulation, and weight management without affecting blood sugar.
Semaglutide
≥99.5% purity · 4113.6 Da
Long-acting GLP-1 receptor agonist studied for weight loss, blood sugar regulation, and cardiovascular protection.
Tirzepatide
≥99.5% purity · 4813.5 Da
Dual GIP/GLP-1 receptor agonist with superior weight loss outcomes vs. GLP-1 monotherapy. Up to 22% body weight reduction in trials.